NCT05493566 2026-02-12
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Emory University
Phase EARLY_PHASE1 Recruiting
Clinical Trials
5 trialsNCT04677361 2021-10-08
Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab
Fox Chase Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT03224871 2020-04-07
UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.
University of California, Davis
Phase EARLY_PHASE1 Completed
NCT03574220 2020-04-07
Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT03371992 2020-03-27
NO3DEXPL
Nilogen Oncosystems
Phase EARLY_PHASE1 Unknown